Uptravi is used to treat pulmonary arterial hypertension pah uptravi helps. Review the guide for female patients with the patient. This information does not take the place of talking to your healthcare provider about your medical condition or your. And 2 patient is not taking orenitram or uptravi in combination with a prostanoidprostacyclin analogue e.
Please see full prescribing information and patient information at. Our goal is that you will feel less short of breath and be able to do more without getting as tired. To receive farther information about uptravi and its effects, talk to your doctor. Uptravi has vasodilatory properties that may result in lowering of blood pressure. Do not use uptravi for a condition for which it was not. Additionally, consider providing the treatment plan, patient prognosis, and any other pertinent medical information to support why uptravi is medically necessary for this patient. You may contact paramount by phone at 14198872520 with questions regarding the prior authorization process. Actelion receives us fda approval of uptravi selexipag. Cvs caremark administers the prescription benefit plan for the.
A registry for patients taking uptravi full text view. For each version, we show the dates it was published on medicines. This patients benefit plan requ ires prior authorization for certain medications in order for the drug to be covered. Uptravi offers patients an oral treatment that targets the prostacyclin pathway, opening the way for oral combination therapies with proven longterm outcome benefits. Selexipag is an oral medication called a prostacyclin ip receptor agonist indicated for the treatment of pulmonary arterial. The following information contains certain forwardlooking statements, relating to the companys business, which can be identified by the use of forwardlooking terminology such. Reallife data on selexipag for the treatment of pulmonary.
Uptravi is not recommended for use while breastfeeding. Our uptravi selexipag tablets side effects drug center provides a comprehensive view of available drug information on the potential side effects when taking this medication. Does the patient have a diagnosis of pulmonary arterial hypertension pah who group 1 and. Our uptravi selexipag tablets side effects drug center provides a comprehensive view of available drug information. Until now the options for treatments targeting the prostacyclin pathway have been limited, and were burdensome for the patient. There is limited experience with abrupt discontinuation of uptravi in patients. This information does not take the place of talking to your. The information in this document is intended to help canadian health care. Prescribing information for uptravi, including patient product information. Letter of appeal actelion pathways patient assistance. Uptravi fda prescribing information, side effects and uses. If patient is maintained at 5 mcg 10 mcgml dose and repeatedly experiences extended treatment times, consider transitioning to 5 mcg 20 mcgml.
Uptravi can help delay slow down the progression of your disease and lower your risk of being hospitalized for pah. How many tablets does the patient need per day after initiationtitration. The following information contains certain forwardlooking statements, relating to the. This could include test and lab results, hospital admission information, please summarize the clinical rationale for prescribing uptravi for this patient. Supplemental material for reallife data on selexipag for the. Uptravi is used to treat pulmonary arterial hypertension pah uptravi helps keep your condition from getting worse and helps lower your risk of needing to be hospitalized for pah.
General information about the safe and effective use of uptravi. The patient information has been approved by the u. Tell your doctor if you are pregnant or become pregnant while using uptravi. Yes no if yes, please select one option for home visits. And 2 patient is not taking orenitram or uptravi in combination with a prostanoidprostacyclin analogue. The dose is then increased by 200mcg twice daily every week to the highest dose a patient can tolerate up to a. Uptravi is used to treat pulmonary arterial hypertension pah. Atln pulmonary arterial hypertension drug, uptravi. Patients obtain selexipag through a prescription from their pulmonary. Sep 12, 2019 tell your doctor if you are pregnant or become pregnant while using uptravi.
Actelion, a division of janssencilag international nv. Twentysix patients were treated with selexipag, of whom 23 had pah and. I understand that blue cross nc may request medical records for this patient at any time in order to verify this information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. Uptravi is a prescription drug approved by the food and drug administration fda to delay disease progression and reduce the risk of hospitalization in cases of pulmonary arterial hypertension pah. Take this medicine exactly as directed by your doctor. For va patients only uptravi selexipag prescription form. I understand that once my information is shared with actelion, my information. For more information about treatment with uptravi, read the package leaflet also part of the epar or contact your doctor or pharmacist. For more information about treatment with uptravi, read the package leaflet. Yes no does the patient have a diagnosis of pulmonary arterial hypertension who. Highlights of prescribing information these highlights do not include all the information needed to use uptravi safely and effectively. To learn more about orenitram, talk with your healthcare provider. Fax completed form and copy of patients insurance card to 18662790669 andor include copy of patient demo from electronic medical records atient information 1.
See what others have said about uptravi, including the effectiveness, ease of use and side effects. A registry for patients taking uptravi sphere the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Uptravi selexipag tablet, coated uptravi titration pack selexipag actelion pharmaceuticals us, inc. The european commission granted a marketing authorisation valid throughout the european union for uptravi on 12 may 2016. Dosing of selexipag uptravi the starting dose of selexipag is 200 mcg twice daily. Do not use uptravi for a condition for which it was not prescribed. I am a healthcare professional in the us i am a patient or caregiver in the us. Uptravi 1,000 microgram filmcoated tablets patient information leaflet pil.
These are not all the possible side effects of uptravi. Product subject to medical prescription which may not be renewed a patient information leaflet patient information leaflet last updated on medicines. Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Uptravi has been approved in germany since may 2016 for adults with pulmonary arterial hypertension high blood pressure. Uptravi lowers blood pressure in your lungs by dilating widening blood vessels that supply blood to the lungs. Uptravi selexipag is a prescription medicine used to treat pulmonary arterial hypertension pah, who group 1, which is high blood pressure in the arteries of your lungs. Uptravi selexipag for patients prescribed uptravi for pulmonary arterial hypertension. This medicine comes with a patient information insert. Uptravi selexipag 18668401509 the most current version of this form supersedes all prior versions. Additionally, consider providing the treatment plan, patient prognosis, and any other pertinent medical information. Sep 10, 2019 the patient information has been approved by the u.
I am a healthcare professional in the us i am a patient or caregiver in the us, 18 years of age or older. The risk information provided here is not comprehensive. However, if a patient reaches a dose that cannot be tolerated, the dose should be reduced to the previous dose level. Uptravi is used for the longterm treatment of pulmonary arterial hypertension pah in adult patients. Yes no select if the patients pulmonary arterial hypertension pah was caused by the following. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged. What is a patient information leaflet and why is it useful. If patient is maintained at ventavis 5 mcg 10 mcgml for 1 month, consider transitioning to ventavis 5 mcg 20 mcgml starting at month 2, unless contacted by physician. Feb 26, 2020 the patient information leaflet pil is the leaflet included in the pack with a medicine. Read this patient information before you start taking uptravi and each time you get a refill. For all female patients access this form online at. Nov 06, 2019 uptravi lowers blood pressure in your lungs by dilating widening blood vessels that supply blood to the lungs. The safety of uptravi has been evaluated in a longterm, placebocontrolled study enrolling 1156 patients with symptomatic pah griphon study see clinical studies 14.
Uptravi selexipag for pulmonary hypertension myphteam. Information is based on the united states food and drug administration drug labeling. Fax completed form and copy of patients insurance card to 18662790669 andor include copy of patient demo from electronic medical records 1. It is written for patients and gives information about taking or using a medicine. For more information, ask your doctor or pharmacist. What uptravi is and what it is used for uptravi is a medicine that contains the active substance selexipag. Highlights of prescribing information these highlights do not include all the information needed to use symtuza safely and effectively. Actelion receives approval for uptravi selexipag for the. The dose is then increased by 200mcg twice daily every week to the highest dose a patient can tolerate up to a maximum dose of 1,600mcg twice daily. The patient titration guide along with the patient information leaflet should be. Find patient medical information for uptravi oral on webmd including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. Side effects of uptravi uptravi selexipag tablets, warnings.
This information does not take the place of talking to your healthcare provider. Symtuza darunavir, cobicistat, emtricitabine, and tenofovir. An independent licensee of the blue cross and blue shield association. Sep 12, 2019 keep uptravi and all medicines out of the reach of children. Yes no does the patient have a diagnosis of pulmonary arterial hypertension who group 1. Ema examines key actelion med uptravi following 5 patient deaths in france. Before prescribing uptravi, physicians should carefully consider whether patients with certain underlying conditions could be adversely affected by vasodilatory effects e. Selexipag uptravi treatments for pulmonary hypertension issued by phas scientific leadership council.
Sep 11, 2017 a registry for patients taking uptravi sphere the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Uptravi 1,000 microgram filmcoated tablets patient. In a phase 3 placebo controlled study in patients with pah, mean absolute changes in hemoglobin. However, plans with a set copayment may result in a cost to the patient.
The patient information leaflet pil is the leaflet included in the pack with a medicine. The european medicines agency told doctors today that they can continue to prescribe actelions vtx. Please fax signed forms to paramount at 18442562025. Is uptravi being prescribed by a pulmonologist, cardiologist, nephrologist, or rheumatologist. Uptravi selexipag dosing, indications, interactions. Please confirm you are a healthcare professional to continue. Uptravi helps keep your condition from getting worse and helps lower your risk of needing to be hospitalized for pah. Selexipag uptravi pulmonary hypertension association. Cvs caremark administers the prescription benefit plan for the patient identified. When a pharmaceutical company changes any document, a new version is published on medicines. The form may be modified without notice to you and we reserve the right to accept only the current version. Listing a study does not mean it has been evaluated by the u. I further certify that the patients medical records accurately reflect the information provided. This information is intended for us healthcare professionals.
Specialty pharmacy clinician to assess patient with each dose. Patient information uptravi uptravee selexipag tablets. Patients obtain selexipag through a prescription from their pulmonary hypertension specialist. Symtuza darunavir, cobicistat, emtricitabine, and tenofovir alafenamide tablets, for oral use initial u. Orenitram treprostinil extendedrelease tablets pah. You may contact paramount by phone at 14198872520 with questions regarding the prior. Information to be completed by prescribing physician. Also, do not stop taking this medicine without checking with your doctor first. Hyperthyroidism was observed in 1% n8 of patients on uptravi and in none of the patients on placebo.
3 1433 1274 220 869 658 1346 1590 327 270 553 623 483 1076 457 1361 1351 7 272 9 1191 1531 138 879 1200 1265 1247 1043 743 1287 340 1024 1384 167 1396 808 1260 243 28 1240 1113 678 1098 1278 1181 201 1429 1096